keyword
MENU ▼
Read by QxMD icon Read
search

Adverse drug events

keyword
https://www.readbyqxmd.com/read/27935737/low-level-laser-therapy-for-reducing-the-hip-waist-and-upper-abdomen-circumference-of-individuals-with-obesity
#1
Gregory C Roche, Steven Shanks, Robert F Jackson, Laura Jane Holsey
OBJECTIVE: To assess the effectiveness of low-level laser therapy (LLLT) for reducing hip, thigh, and abdomen circumference of individuals with body-mass index (BMI) between 30 and 40 kg/m(2). BACKGROUND: Previous studies demonstrated the effectiveness of LLLT for reducing body circumference in the hips, thighs, and abdomen of nonobese individuals with a BMI <30 kg/m(2). METHODS: In this randomized, double-blind sham-controlled study, obese, but otherwise healthy, individuals were randomized to undergo 30-min LLLT (n = 28) or sham treatments (n = 25) three times weekly for 4 weeks...
December 9, 2016: Photomedicine and Laser Surgery
https://www.readbyqxmd.com/read/27935123/efficacy-and-safety-of-nucleoside-antiviral-drugs-for-treatment-of-recurrent-herpes-labialis-a-systematic-review-and-meta-analysis
#2
REVIEW
Fangman Chen, Hao Xu, Jinli Liu, Yuan Cui, Xiaobo Luo, Yu Zhou, Qianming Chen, Lu Jiang
OBJECTIVES: To evaluate the effectiveness and safety of nucleoside antiviral drugs for the treatment of recurrent herpes labialis. METHODS: Randomized controlled trials that examined the effectiveness and/or safety of nucleoside antiviral drugs for recurrent herpes labialis were identified via a literature search. The parameters used to measure efficacy were time-to-healing of classic and all lesions, time-to-resolution of pain, and percentage of aborted lesions...
December 9, 2016: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/27935018/tolerability-and-efficacy-of-perampanel-in-children-with-refractory-epilepsy
#3
Eli Heyman, Eli Lahat, Noa Levin, Orna Epstein, Mirit Lazinger, Matitiahu Berkovitch, Revital Gandelman-Marton
AIM: There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic drug with a novel mechanism of action, in children and adolescents. We aimed to describe our experience with perampanel add-on and mono-therapy in children with refractory epilepsy. METHOD: Computerized medical records of children treated with perampanel in the paediatric neurology clinic from December 2012 to October 2015 were reviewed. RESULTS: Twenty-four children treated with perampanel (15 females, 9 males) aged 1 year 6 months to 17 years (mean 10y, standard deviation [SD] 4y 5mo) were identified...
December 9, 2016: Developmental Medicine and Child Neurology
https://www.readbyqxmd.com/read/27935017/early-esli-study-long-term-experience-with-eslicarbazepine-acetate-after-first-monotherapy-failure
#4
V Villanueva, P Bermejo, J Montoya, M Toledo, A Gómez-Ibáñez, M Garcés, L Vilella, F J López-González, X Rodriguez-Osorio, D Campos, P Martínez, P Giner, J Zurita, J Rodríguez-Uranga, J Ojeda, J A Mauri, J L Camacho, J Ruiz-Giménez, J J Poza, A Massot-Tarrús, M L Galiano, M Bonet
PURPOSE: Evaluate real-life experience with eslicarbazepine acetate (ESL) after first monotherapy failure in a large series of patients with focal epilepsy. METHOD: Multicentre, retrospective, 1-year, observational study in patients older than 18 years, with focal epilepsy, who had failed first antiepileptic drug monotherapy and who received ESL. Data from clinical records were analysed at baseline, 3, 6 and 12 months to assess effectiveness and tolerability. RESULTS: Eslicarbazepine acetate was initiated in 253 patients...
December 9, 2016: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27934657/the-importance-of-quality-specifications-in-safety-assessments-of-amino-acids-the-cases-of-l-tryptophan-and-l-citrulline
#5
REVIEW
Hellen A Oketch-Rabah, Amy L Roe, Bill J Gurley, James C Griffiths, Gabriel I Giancaspro
The increasing consumption of amino acids from a wide variety of sources, including dietary supplements, natural health products, medical foods, infant formulas, athletic and work-out products, herbal medicines, and other national and international categories of nutritional and functional food products, increases the exposure to amino acids to amounts far beyond those normally obtained from the diet, thereby necessitating appropriate and robust safety assessments of these ingredients. Safety assessments of amino acids, similar to all food constituents, largely rely on the establishment of an upper limit [Tolerable Upper Intake Level (UL)] considered to be a guide for avoiding high intake, above which adverse or toxic effects might occur...
December 2016: Journal of Nutrition
https://www.readbyqxmd.com/read/27934558/fibroblast-growth-factor-23-in-postrenal-transplant-an-often-forgotten-hormone
#6
Fateme Shamekhi Amiri, Mohammad Reza Khatami
Fibroblast growth factor 23 is likely to be the most important regulator of phosphate homeostasis, which mediates its functions through fibroblast growth factor receptors and the coreceptor Klotho. In addition to reducing expression of the sodium-phosphate cotransporters NPT2a and NPT2c in the proximal tubules, fibroblast growth factor 23 inhibits renal 1α-hydroxylase and stimulates 24-hydroxylase and appears to reduce parathyroid hormone secretion in short-term studies. Fibroblast growth factor 23 synthesis and secretion by osteocytes and osteoblasts are upregulated through 1,25-dihydroxyvitamin D3 and through an increased dietary phosphate intake...
December 2016: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27933615/immediate-release-versus-controlled-release-carbamazepine-in-the-treatment-of-epilepsy
#7
REVIEW
Graham Powell, Matthew Saunders, Alexandra Rigby, Anthony G Marson
BACKGROUND: Carbamazepine (CBZ) is a commonly used drug for epilepsy that is associated with troublesome adverse events including dizziness, double vision, drowsiness, poor co-ordination and unsteadiness. These adverse events often occur during peaks in drug plasma concentration. These adverse events may limit the daily dose of CBZ that can be tolerated and reduce the chances of seizure control in patients who require high doses. A controlled-release formulation of CBZ delivers the same dose over a longer period of time when compared to a standard immediate-release formulation, thereby reducing post-dose peaks in CBZ plasma concentration and potentially reducing adverse events...
December 8, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27933192/randomised-comparison-of-drug-eluting-versus-bare-metal-stenting-in-patients-with-non-st-elevation-myocardial-infarction
#8
Wouter S Remkes, Erik A Badings, Renicus S Hermanides, Saman Rasoul, Jan-Henk E Dambrink, Petra C Koopmans, Salem Hk The, Jan Paul Ottervanger, A T Marcel Gosselink, Jan Ca Hoorntje, Harry Suryapranata, Arnoud Wj van 't Hof
OBJECTIVE: The superiority of drug-eluting stents (DES) over bare-metal stents (BMS) in patients with ST elevation myocardial infarction (STEMI) is well studied; however, randomised data in patients with non-ST elevation myocardial infarction (NSTEMI) are lacking. The objective of this study was to investigate whether stenting with everolimus-eluting stents (EES) safely reduces restenosis in patients with NSTEMI as compared to BMS. METHODS: ELISA-3 patients were asked to participate in the angiographic substudy and were randomised to DE (Xience V) or BM (Vision) stenting (ELISA-3 group)...
2016: Open Heart
https://www.readbyqxmd.com/read/27932982/impact-of-cyp2c19-variants-on-clinical-efficacy-of-clopidogrel-and-1-year-clinical-outcomes-in-coronary-heart-patients-undergoing-percutaneous-coronary-intervention
#9
Hong Sun, Qiang Qu, Zhen-Fan Chen, Sheng-Lan Tan, Hai-Jun Zhou, Jian Qu, Hui Chen
The impact of pharmacogenetic variants of cytochrome P450 2C19 (CYP2C19) on clopidogrel-mediated effects on platelet inhibition, inflammatory response and endothelial function, as well as risk of major adverse cardiovascular events (MACE), in coronary heart patients undergoing percutaneous coronary intervention (PCI) was investigated. To this end, we assessed the residual platelet aggregation rate (RPA), maximal aggregation rate (MAR) and plasma levels of sCD40L, sP-selectin, MMP-9, sVCAM-1 and sE-selectin after 24 h of PCI in 559 patients treated with clopidogrel and followed up for 1 year for evidence of MACE...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27932608/antiviral-activity-of-pocapavir-in-a-randomized-blinded-placebo-controlled-human-oral-poliovirus-vaccine-challenge-model
#10
Marc S Collett, Jeffrey R Hincks, Kimberley Benschop, Erwin Duizer, Harrie van der Avoort, Eric Rhoden, Hongmei Liu, M Steven Oberste, Mark A McKinlay, Marianne Hartford
BACKGROUND: Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat. METHODS: In a randomized, blinded, placebo-controlled study, adults were challenged with oral poliovirus vaccine type 1 (mOPV1) and subsequently treated with capsid inhibitor pocapavir or placebo. Time to virus negativity in stool was determined. RESULTS: 144 participants were enrolled; 98% became infected upon OPV challenge...
December 8, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27932570/effect-of-losartan-combined-with-amlodipine-or-with-a-thiazide-on-uric-acid-levels-in-hypertensive-patients
#11
Alberto F Rubio-Guerra, Ana K Garro-Almendaro, Cesar I Elizalde-Barrera, Juan A Suarez-Cuenca, Montserrat B Duran-Salgado
: Hyperuricemia leads to endothelial dysfunction and insulin resistance, and has been associated with diseases such as hypertension. Antihypertensive drugs modify serum uric acid levels, however, few data are available about their combinations on uricemia. In this study we evaluate the effect of two combinations of losartan, with amlodipine or with hydrochlorothiazide, on serum uric acid levels in hypertensive patients. METHODS: A total of 60 hypertensive patients were randomized in two groups; group LA received losartan/amlodipine (100/5 mg) once a day, whereas LH group received losartan hydrochlorothiazide (100/12...
December 8, 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27932229/regorafenib-for-patients-with-hepatocellular-carcinoma-who-progressed-on-sorafenib-treatment-resorce-a-randomised-double-blind-placebo-controlled-phase-3-trial
#12
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Ann-Lii Cheng, Josep M Llovet, Richard S Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han
BACKGROUND: There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment. METHODS: In this randomised, double-blind, parallel-group, phase 3 trial done at 152 sites in 21 countries, adults with HCC who tolerated sorafenib (≥400 mg/day for ≥20 of last 28 days of treatment), progressed on sorafenib, and had Child-Pugh A liver function were enrolled...
December 5, 2016: Lancet
https://www.readbyqxmd.com/read/27932068/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent-small-cell-lung-cancer-a-first-in-human-first-in-class-open-label-phase-1-study
#13
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, Neal Ready, Daniel Morgensztern, Bonnie S Glisson, Lauren A Byers, Melissa L Johnson, Howard A Burris, Francisco Robert, Tae H Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K Strickland, Ramaswamy Govindan, Scott J Dylla, Stanford L Peng, David R Spigel
BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen. METHODS: We conducted a phase 1 open-label study at ten cancer centres in the USA...
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27931828/targeting-mtor-pathway-in-gynecological-malignancies-biological-rationale-and-systematic-review-of-published-data
#14
REVIEW
Loay Kassem, Omar Abdel-Rahman
BACKGROUND: mTOR inhibitors are widely used in different malignancies with several trials testing their efficacy and safety in gynecological malignancies. We aimed to review the current evidence that support the expansion of using such drugs in the treatment of advanced gynecological cancers. METHODS: A comprehensive systematic review of literature has been conducted to include prospective trials that used everolimus, temsirolimus or ridaforolimus in the management of gynecological cancers and have available efficacy and toxicity results...
December 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27931296/intravenous-and-subcutaneous-immunoglobulin-g-replacement-therapy
#15
Francisco A Bonilla
Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy. IgG for replacement is most often administered via the intravenous IgG (IVIG) or subcutaneous IgG (SCIG) routes. IVIG is usually administered every 34 weeks, and SCIG is usually administered weekly, although variations may be considered in all cases...
November 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/27931077/antibiotics-for-the-neurological-complications-of-lyme-disease
#16
REVIEW
Diego Cadavid, Paul G Auwaerter, Jeffrey Rumbaugh, Harald Gelderblom
BACKGROUND: Various central nervous system-penetrant antibiotics are bactericidal in vitro and in vivo against the causative agent of Lyme neuroborreliosis (LNB), Borrelia burgdorferi. These antibiotics are routinely used clinically to treat LNB, but their relative efficacy is not clear. OBJECTIVES: To assess the effects of antibiotics for the treatment of LNB. SEARCH METHODS: On 25 October 2016 we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase...
December 9, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27930941/evaluation-of-a-new-low-dose-levonorgestrel-intrauterine-contraceptive-system-over-5-years-of-use
#17
Kristina Gemzell-Danielsson, Dan Apter, Sylvia Dermout, Thomas Faustmann, Kimberly Rosen, Thomas Schmelter, Martin Merz, Anita Nelson
OBJECTIVE: To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use. STUDY DESIGN: In this Phase III study, 2885 nulliparous and parous women aged 18-35 years were randomized to LNG-IUS 8 or LNG-IUS 12 for 3 years. After 3 years, women using LNG-IUS 12 could continue for up to 2 additional years (5 years total). The primary outcome was occurrence of pregnancy (Pearl Index). Secondary outcomes included safety, bleeding, dysmenorrhea, discontinuations, and user satisfaction...
November 20, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27930472/risks-associated-with-lentiviral-vector-exposures-and-prevention-strategies
#18
Ryan Schlimgen, John Howard, Dawn Wooley, Maureen Thompson, Lindsey R Baden, Otto O Yang, David C Christiani, Gustavo Mostoslavsky, David V Diamond, Elizabeth Gilman Duane, Karen Byers, Thomas Winters, Jeffrey A Gelfand, Gary Fujimoto, T Warner Hudson, Jatin M Vyas
Lentiviral vectors (LVVs) are powerful genetic tools that are being used with greater frequency in biomedical laboratories and clinical trials. Adverse events reported from initial clinical studies provide a basis for risk assessment of occupational exposures, yet many questions remain about the potential harm that LVVs may cause. We review those risks and provide a framework for principal investigators, Institutional Biosafety Committees, and occupational health professionals to assess and communicate the risks of exposure to staff...
December 2016: Journal of Occupational and Environmental Medicine
https://www.readbyqxmd.com/read/27928726/evaluating-the-safety-profile-of-non-active-implantable-medical-devices-compared-with-medicines
#19
REVIEW
Josep Pane, Preciosa M Coloma, Katia M C Verhamme, Miriam C J M Sturkenboom, Irene Rebollo
Recent safety issues involving non-active implantable medical devices (NAIMDs) have highlighted the need for better pre-market and post-market evaluation. Some stakeholders have argued that certain features of medicine safety evaluation should also be applied to medical devices. Our objectives were to compare the current processes and methodologies for the assessment of NAIMD safety profiles with those for medicines, identify potential gaps, and make recommendations for the adoption of new methodologies for the ongoing benefit-risk monitoring of these devices throughout their entire life cycle...
December 7, 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27928718/sofosbuvir-velpatasvir-a-pangenotypic-drug-to-simplify-hcv-therapy
#20
REVIEW
Rebecca Lee, Shyam Kottilil, Eleanor Wilson
Treatment for chronic hepatitis C virus (HCV) has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. Although significant improvement in sustained virologic responses (SVR) has been reported with new DAAs for genotypes 1 and 4, effective treatments for genotype 3 have been lacking, and a single pill that can yield high SVR rates against HCV genotypes 1-6 has not been available until now...
December 7, 2016: Hepatology International
keyword
keyword
979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"